Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Non Operating Investment Income (2016 - 2023)

Historic Non Operating Investment Income for Silo Pharma (SILO) over the last 9 years, with Q3 2023 value amounting to $2558.0.

  • Silo Pharma's Non Operating Investment Income rose 10168.64% to $2558.0 in Q3 2023 from the same period last year, while for Dec 2023 it was -$560.0, marking a year-over-year increase of 9978.99%. This contributed to the annual value of -$3118.0 for FY2023, which is 9702.2% up from last year.
  • According to the latest figures from Q3 2023, Silo Pharma's Non Operating Investment Income is $2558.0, which was up 10168.64% from -$3508.0 recorded in Q2 2023.
  • Silo Pharma's Non Operating Investment Income's 5-year high stood at $6.7 million during Q3 2021, with a 5-year trough of -$161798.0 in Q1 2022.
  • Its 3-year average for Non Operating Investment Income is $710380.6, with a median of $390.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in Silo Pharma's Non Operating Investment Income was 272830.51% (2022), while the steepest drop was 10227.92% (2022).
  • Over the past 3 years, Silo Pharma's Non Operating Investment Income (Quarter) stood at $5363.0 in 2021, then soared by 2728.31% to $151682.0 in 2022, then crashed by 98.31% to $2558.0 in 2023.
  • Its Non Operating Investment Income stands at $2558.0 for Q3 2023, versus -$3508.0 for Q2 2023 and $390.0 for Q1 2023.